Travere Therapeutics Inc. (TVTX)
NASDAQ (NMS) NASDAQ (NMS) Primary 
TVTX Stock Falls as FDA Extends Review Timeline for Filspari sNDA
Travere Therapeutics shares fall after the FDA extends its review timeline for Filspari's sNDA in FSGS, pushing the decision date to April 2026.
Options Bears Eye Plummeting Biotech Stock
Biotech stock Travere Therapeutics Inc (NASDAQ:TVTX) is plummeting today, down 32.8% to trade at $22.92 at last glance, after news that the Food & Drug Administration (FDA) has new questions regarding its Filspari application, which could cause a potential delay for the serious kidney disease treatment.
Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Travere Therapeutics, Inc. (TVTX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Travere Therapeutics, Inc. (TVTX) Q3 2025 Earnings Call Transcript
Travere Therapeutics, Inc. ( TVTX ) Q3 2025 Earnings Call October 30, 2025 4:30 PM EDT Company Participants Nivi Nehra - Vice President of Corporate Communications & Investor Relations Eric Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Peter Heerma - Chief Commercial Officer Chris Cline - Chief Financial Officer William Rote - Chief Research Officer Conference Call Participants Joseph Schwartz - Leerink Partners LLC, Research Division Laura Chico - Wedbush Securities Inc., Research Division Anupam Rama - JPMorgan Chase & Co, Research Division Yigal Nochomovitz - Citigroup Inc. Exchange Research Gavin Clark-Gartner - Evercore ISI Institutional Equities, Research Division Mohit Bansal - Wells Fargo Securities, LLC, Research Division Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Maurice Raycroft - Jefferies LLC, Research Division Jason Zemansky - BofA Securities, Research Division Alexander Thompson - Stifel, Nicolaus & Company, Incorporated, Research Division Joseph Pantginis - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Good afternoon, and welcome to the Travere Therapeutics' Third Quarter 2025 Financial Results Conference Call.
Travere (TVTX) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates
While the top- and bottom-line numbers for Travere (TVTX) give a sense of how the business performed in the quarter ended September 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Travere Therapeutics (TVTX) Beats Q3 Earnings and Revenue Estimates
Travere Therapeutics (TVTX) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of a loss of $0.31 per share. This compares to a loss of $0.7 per share a year ago.
TVTX Stock Soars as FDA Waives Advisory Committee for Filspari sNDA
Travere Therapeutics stock jumps after the FDA drops advisory meeting for Filspari's FSGS filing, with approval decision due in January 2026.
Strength Seen in Travere (TVTX): Can Its 26.2% Jump Turn into More Strength?
Travere (TVTX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
Travere Therapeutics, Inc. (TVTX) Presents at Cantor Global Healthcare Conference 2025 Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Cantor Global Healthcare Conference 2025 September 4, 2025 2:45 PM EDT Company Participants Eric Dube - President, CEO & Director Peter Heerma - Chief Commercial Officer Conference Call Participants Prakhar Agrawal - Cantor Fitzgerald & Co., Research Division Presentation Prakhar Agrawal Senior Biotech Analyst All right. Hello, everyone.
Travere Therapeutics, Inc. (TVTX) Q2 2025 Earnings Call Transcript
Travere Therapeutics, Inc. (NASDAQ:TVTX ) Q2 2025 Earnings Conference Call August 6, 2025 4:30 PM ET Company Participants Christopher Cline - Chief Financial Officer Eric M. Dube - President, CEO & Director Jula Inrig - Chief Medical Officer Nivi Nehra - Corporate Participant e - Corporate Participant V - Corporate Participant i - Corporate Participant c - Corporate Participant P - Corporate Participant r - Corporate Participant e - Corporate Participant s - Corporate Participant i - Corporate Participant d - Corporate Participant Communications & Investor Relations - Corporate Participant e - Corporate Participant n - Corporate Participant t - Corporate Participant o - Corporate Participant f - Corporate Participant o - Corporate Participant r - Corporate Participant p - Corporate Participant o - Corporate Participant r - Corporate Participant a - Corporate Participant t - Corporate Participant e - Corporate Participant Peter Heerma - Chief Commercial Officer William E.
Here's What Key Metrics Tell Us About Travere (TVTX) Q2 Earnings
Although the revenue and EPS for Travere (TVTX) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Travere Therapeutics (TVTX) Reports Q2 Loss, Tops Revenue Estimates
Travere Therapeutics (TVTX) came out with a quarterly loss of $0.14 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.9 per share a year ago.
